Charged Alpha Stock Encyclopedia

United Microelectronics Corporation (UMC) Q2 2026 — United Microelectronics (UMC), Taiwan's mature-node specialty foundry, reported Q2 2026 revenue of NT$68.73B (US$2.18B, +12.6% QoQ, +17.0% YoY) at the top end of guidance, gross margin up to 32.5% from 29.2%, operating income up 32.6% to NT$14.95B on utilization of 85% and wafer shipments up 10.6%. Net income attributable of NT$42.26B was up 161% QoQ - EPS NT$3.39, or US$0.537 per ADS against a consensus of about US$0.158. But NT$30.24B of that pre-tax profit was NET NON-OPERATING INCOME, up 463% QoQ and 67% of pre-tax profit, and the earnings deck never says what it was. Core operating EPS taxed at a normal 17% is about US$0.157 per ADS - almost exactly the consensus. The entire beat was the line the company did not explain. Management also raised 2026 capex from $1.5B to $2.0B, approved roughly $5B of phased expansion across 2026-27 (Singapore P4 cleanroom plus a new Tainan fab shell), and guided depreciation to grow low-teens percent for at least two years. Our call: AVOID, 3/5, fair value $11.50 per ADS versus $17.11 - and no cell in our mid-cycle grid reaches today's price.

UMC just reported net income up 161% in a single quarter and beat the analyst estimate by thirty-eight cents a share - and the stock did essentially nothing. That was not a market failure. Q2 2026 revenue was NT$68.73 billion (about US$2.18 billion), up 12.6% sequentially and 17% year over year, at the top end of guidance. Gross margin expanded from 29.2% to 32.5%. Operating income rose 32.6% to NT$14.95 billion. All of that is real. But net income attributable was NT$42.26 billion, and pre-tax profit was NT$45.19 billion - which means NT$30.24 billion, sixty-seven percent of pre-tax profit, was NET NON-OPERATING INCOME, up 463% from NT$5.4 billion in Q1. The earnings materials do not tell you what it was. Tax the operating line at a normal 17% and core earnings come to about 15.7 US cents per ADS. The consensus estimate was 15.8 cents. On the business of making chips, UMC delivered exactly what was expected. Meanwhile management raised 2026 capex from $1.5 billion to $2.0 billion, approved roughly $5 billion of phased expansion, and guided depreciation to grow low-teens percent for at least two years - into a quarter already running 85% utilization. Our mid-cycle model says $11.50 per ADS against $17.11 today.

THE CALL: AVOID (3/5, A REAL OPERATING QUARTER WRAPPED IN A HEADLINE THAT IS NOT REPEATABLE) — base-case value ~$11.50 vs ~$17.11 today.

What to watch: Silicon photonics revenue disclosed as its own line and large enough to matter once the 12-inch platform opens to general customers in 2027, plus the Intel 12nm collaboration hitting its milestones on schedule - PDK complete late 2026, tape-outs in 2027, meaningful production 2028. Either would convert optionality into an actual earnings estimate and we would raise the multiple, not just the numbers. The near-term risk to respect is the non-operating line: whatever produced NT$30.24 billion this quarter almost certainly does not recur, so Q3 net income can fall sharply while the foundry itself gets better - utilization above 90% and gross margin in the mid-30s alongside a net income number that looks like a collapse.

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

SK hynix Inc. (SKHY) Q2 2026 — SK hynix (SKHY), the HBM leader that supplies the memory stacked next to nearly every AI accelerator, reported the largest quarter in Korean corporate history: revenue KRW 79.3T (+257% YoY), operating profit KRW 60.5T at a 76% margin (+557%), and net profit KRW 93.9T - a 118% net margin, meaning profit exceeded revenue. But it MISSED (street: KRW 84T revenue / KRW 64T operating profit), the margin beat came from commodity NAND (ASP +mid-50% QoQ) rather than HBM, and KRW 63.3T of that net profit is an unrealized fair-value mark on its Kioxia stake - a position with no board seat and no voting rights, on a stock that has since fallen 57%. Core net income ex-Kioxia is roughly KRW 45.5T. The Nasdaq ADR (listed July 10 in a record $26.5B offering at $149) trades near $127, about 31% ABOVE the identical Seoul shares, and the ordinary-to-ADR conversion quota was fully consumed at listing. Our mid-cycle model: $99 per ADS. Our call: AVOID.

SK hynix just did something companies are not supposed to be able to do: it reported a quarterly profit LARGER than its quarterly revenue. Q2 2026 revenue of KRW 79.3 trillion (+257% YoY), operating profit of KRW 60.5 trillion at a 76% operating margin (+557% YoY), and net profit of KRW 93.9 trillion - a 118% net margin, and the fifth consecutive record quarter. The tax bill alone, KRW 28.8 trillion, was the largest single quarter of corporate tax ever paid by a Korean company. And yet three things are wrong with the picture. First, it was a MISS: the Street modelled KRW 84 trillion of revenue and KRW 64 trillion of operating profit, and SK hynix came in ~5.5% and ~6.6% light, because 'shipments of some high value added products were pushed into the second half' - the HBM4 ramp slipped. Second, the record margin was disproportionately a NAND story: NAND ASPs rose in the mid-50% range versus ~30% for DRAM, and NAND climbed from 21% to 27% of revenue while DRAM fell from 78% to 73%. Third, and biggest: KRW 63.3 trillion of that net profit is a Level-3 fair-value mark on SK hynix's Kioxia stake - held through a Cayman holding company with no board seat and no significant influence, roughly 80% unrealized - and Kioxia has since fallen ~57% from the June 30 price that set the mark. Strip it and tax it at the company's own 23.5% effective rate and core net income is about KRW 45.5 trillion, core EPS ~KRW 64,000 against the reported KRW 132,126. Roughly half the headline EPS is a Japanese share price. Then there is the wrapper. The Nasdaq ADR listed on July 10 in a $26.5 billion offering - the largest depositary-share deal in history - priced at $149, opened at $170, peaked at $194, and now trades near $127, about 15% below the IPO price. It also trades roughly 31% ABOVE the identical Seoul-listed shares, and because the ordinary-to-ADR conversion quota (17,790,000 shares, 2.50% of the company) was fully consumed at listing, that premium can only close by the ADR falling. Our valuation uses a mid-cycle earnings frame rather than a DCF, because capex in the high KRW 40 trillion range against ~KRW 16 trillion of annual depreciation makes near-term free cash flow meaningless: KRW 225T of mid-cycle revenue at a 40% through-cycle margin, taxed at 25%, at 13x plus KRW 95,200/share of net cash, gives KRW 1,299,000 per ordinary share - $99 per ADS after the 10:1 ratio, an FX rate of KRW 1,446.7/$, and a 10% structural ADR access premium. Today's Seoul price translates to about $97 per ADS, so two independent roads land two dollars apart, both ~22% below the Nasdaq price. Our call: AVOID, 2/5. This is not a bet against SK hynix the company - the franchise is an A, with 69.4 trillion won of net cash, ~56-62% HBM share and five-year agreements with roughly ten customers. It is a refusal to pay a 31% markup for a half-paper quarter at what may be the top of a memory cycle. We differ sharply from Barclays' Overweight and $330 target and from the Seoul consensus (11 brokers, Buy, KRW 4,060,000, ~$281/ADS) - their multiple is defensible, we just do not believe peak-cycle 2027 earnings are the right base. Interested near parity. Not financial advice.

THE CALL: AVOID (2/5, A HISTORIC QUARTER, A HALF-PAPER PROFIT, AND A 31% MARKUP) — base-case value ~$99 vs ~$127 today.

What to watch: 2027 HBM volume and pricing actually locked with the major customers and disclosed rather than alluded to, plus SK hynix raising the ADR conversion cap so the 31% premium can physically close - either would move us, both together and we would be buyers; the near-term risk to respect is the Kioxia reversal, since the KRW 63.3T gain was struck at a June 30 price and Kioxia has since fallen about 57%, which should swing Q3 non-operating income hard negative

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

NXP Semiconductors N.V. (NXPI) Q2 2026 — NXP Semiconductors (NXPI), the Eindhoven-based chipmaker that derives ~55% of revenue from automotive, reported Q2 2026 (quarter ended June 28, 2026) after the close on July 28: record revenue of $3.496B, up 19.5% YoY and 9.9% sequentially, with non-GAAP EPS of $3.61 beating the $3.50 consensus and GAAP EPS of $3.02. Non-GAAP gross margin expanded 150bps YoY to 58.0% and non-GAAP operating margin rose 310bps to 35.1%. All four end markets grew: Automotive $1,938M (+12.1%, ~+17% ex the MEMS sensor business sold to STMicroelectronics in February), Industrial & IoT $755M (+38.3%), Comms Infrastructure & Other $452M (+41.3%, including a data-center franchise scaling from ~$200M in 2025 to a guided $500M+ in 2026), and Mobile $351M (+6.0%). Q3 guidance was strong: revenue $3.75B at the midpoint (+18% YoY), non-GAAP gross margin 58.5%, operating margin 36.9%, and EPS $4.11. The stock still fell, closing July 29 at $242.51, ~27% below its May 26 high of $332.67. The under-covered number is in the 10-Q: revenue to distributors rose 26.7% YoY (+24.5% YTD) while revenue to direct customers rose just 9.4% (+4.6% YTD) — sell-in to the channel running roughly 5x sell-through to direct buyers, with channel inventory at 11 weeks vs 9 a year ago, even as management said it has not seen restocking. Reported free cash flow of $791M (22.6% of revenue) excludes $186M of foundry joint-venture funding (VSMC/ESMC), which is capacity spending by any economic definition — true FCF is closer to ~$600M, ~17% of revenue. The $104M buyback merely offset $105M of stock-based compensation (diluted shares 254.0M vs 253.8M a year ago). Our normalized owner-earnings DCF on mid-cycle revenue of $14.5B at a 33.5% operating margin, with SBC expensed, yields owner earnings of ~$3.14B ($12.37/sh) and a base-case fair value of $198 — about 18% below the price. Our bull case, assuming management's full 2027 plan ($16B revenue, 37% margins), is $242 — essentially exactly today's price. Our call: AVOID AT THIS PRICE, 2/5 — a quality franchise whose stock already discounts the bull case. Wall Street is bullish (32 buy / 12 hold / 2 sell, $283 average target, $290 median; JPMorgan $300, Bernstein $290, Wells Fargo $290 — all verified current), so we DIFFER, materially more cautious.

NXP Semiconductors (NXPI) just delivered the best second quarter in its history and the stock fell anyway — and the explanation is a line in the 10-Q that almost nobody quoted. NXP is a Dutch-domiciled, Nasdaq-listed chipmaker descended from Philips Semiconductors that bought Freescale a decade ago; roughly 55% of revenue comes from automotive — radar, electrification, in-vehicle networking and the S32 processor family for software-defined vehicles. Q2 2026 (ended June 28, 2026): revenue $3.496B, +19.5% YoY and +9.9% sequentially, a record; non-GAAP EPS $3.61 vs $3.50 consensus; GAAP EPS $3.02; non-GAAP gross margin 58.0% (+150bps) and operating margin 35.1% (+310bps). Q3 guidance was also strong — $3.75B revenue at the midpoint (+18% YoY), 58.5% gross margin, $4.11 EPS. Every end market grew: Industrial & IoT +38.3%, Comms Infrastructure +41.3% on a brand-new data-center franchise scaling from ~$200M to $500M+, Mobile +6.0% — and Automotive, the biggest segment, grew the slowest at +12.1% (~17% adjusting for the MEMS sensor business sold to STMicroelectronics in February). Here is the number that matters: revenue to distributors rose 26.7% YoY and 24.5% year-to-date, while revenue to direct customers — largely the Western Tier 1 auto suppliers — rose just 9.4% and 4.6%. That is roughly five times the growth going into the channel versus to end customers, with channel inventory at 11 weeks against 9 a year ago, even as management stated it has not seen restocking. Two more things deserve scrutiny: the CFO calls margin expansion 'structural' while the actual tailwind is utilization moving from the low-80s to the mid-80s (spendable once) and while flagging that foundry cost increases arrive in 2027 when supply agreements are renegotiated — the same year NXP targets a 60% gross margin. And the reported 22.6% free cash flow margin excludes $186M of VSMC/ESMC joint-venture capacity funding; include it and true FCF is nearer 17% of revenue. Meanwhile the $104M buyback exactly offset $105M of stock compensation, leaving share count flat — that is not returning capital, it is paying employees, which is why we expense SBC. Our normalized owner-earnings DCF (mid-cycle revenue $14.5B, 33.5% operating margin, SBC expensed, 9.5% discount rate) gives owner earnings of ~$3.14B, or $12.37/share, and a base-case fair value of $198 versus $242.51 today — about 18% of downside. Our bear case is $106; our bull case, in which management delivers the full 2027 plan of $16B revenue at 37% margins, is $242 — almost exactly the current price. The reverse DCF says the same: today's price requires owner earnings to compound 10% annually for five years. Our call: AVOID AT THIS PRICE, 2/5 — this is a valuation call, not a quality call. We'd look under ~$170. Wall Street disagrees: 32 buy / 12 hold / 2 sell across 46 analysts, a $283 average target and $290 median (JPMorgan $300, Bernstein raised to $290, Wells Fargo $290 — all verified current, not stale), so we DIFFER and are materially more cautious. Watch the sales-channel split in every 10-Q. Not financial advice.

THE CALL: AVOID AT THIS PRICE (2/5, A GOOD COMPANY WHOSE STOCK ALREADY PAYS FOR THE 2027 BULL CASE — A VALUATION CALL, NOT A QUALITY CALL) — base-case value ~$198.00 vs ~$242.51 today.

What to watch: direct-customer revenue accelerating to match distribution growth, the S32N and S32K5 processors ramping with disclosed revenue, and the data-center franchise clearing $500 million would convert this from a cyclical upswing into durable secular content growth and would move us materially more constructive; the risks to respect are the opposite — channel inventory pushing past 12 weeks, a gross-margin guide that slips as foundry supply agreements reset higher in 2027, or capital returns staying near 45% of free cash flow, any of which would confirm that this quarter's 19% growth was partly inventory rather than consumption

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Rambus Inc. (RMBS) Q2 2026 — Rambus (RMBS), the memory-interface chip and silicon-IP company that sits between the processor and the memory in every AI server, reported Q2 2026 (quarter ended June 30, 2026) after the close on July 27: record revenue of $207.4M (+20% YoY), above its own $192-198M guide; record product revenue of $99.2M (+22% YoY, +13% QoQ); royalties $84.3M (+23%); contract & other $24.0M (+8%). Non-GAAP diluted EPS $0.77 beat the ~$0.73 consensus; GAAP diluted EPS was $0.61. Operating cash flow $61.2M; cash and marketable securities $824.9M with zero debt (~$7.50/share of net cash). But underneath the records: GAAP operating margin FELL from 36.6% to 35.1% on +20% revenue, SG&A rose 36% versus revenue +20%, and Rambus booked a $3.3M restructuring charge plus facility-closure costs. The Q3 guide (revenue $210-216M) has product revenue rising to $110-116M while royalties — the ~100%-incremental-margin line — are guided DOWN to $69-75M, roughly -15% sequentially; licensing billings of $84.1M essentially matched reported royalty revenue and deferred revenue fell from $30.0M to $21.2M, so there is no deferred cash cushion. Stock-based comp was $15.9M, 7.7% of revenue, making non-GAAP EPS 26% higher than GAAP; Rambus repurchased zero shares in the quarter while the stock fell from $170 to $123, and insiders sold 25 times in six months with zero purchases. The company also disclosed in its Q1 2026 10-Q that it is responding to a federal grand jury subpoena in a criminal DOJ antitrust investigation. Our owner-earnings DCF — expensing stock comp honestly rather than using the non-GAAP figure, and adding back the $824.9M of net cash — lands fair value near $72 versus ~$83.21 today. Reverse-DCF: the current price requires ~20% owner-earnings growth per year for five straight years. Our call: AVOID, 3/5 — a great business, still about 13% above our fair value. Wall Street is Buy (11 buy / 3 hold / 0 sell, 14 analysts) with a $147.40 average target implying +77%, so we DIFFER sharply — and note most of those targets are dated April 28, 2026, before the 51% drawdown.

Rambus (RMBS) just delivered the best quarter in its history and the stock fell 14% in two sessions, capping a 51% collapse from its June 3 peak of $170.66 to roughly $83.21 today. Rambus makes the register clock drivers and companion chips that sit on DDR5 memory modules — the bottleneck every AI server is choking on — and licenses memory-interface and security IP. Q2 2026 (ended June 30): record revenue $207.4M (+20% YoY, above the $192-198M guide), record product revenue $99.2M (+22%), royalties $84.3M (+23%), contract & other $24.0M. Non-GAAP EPS $0.77 beat ~$0.73; GAAP EPS was $0.61. Cash and securities $824.9M with zero debt, and $61.2M of operating cash flow. So why the sell-off? Three things the headline buries. First, GAAP operating margin FELL from 36.6% to 35.1% on 20% revenue growth — negative operating leverage in a record quarter — as SG&A jumped 36% and the company took its first restructuring charge in years. Second, the Q3 guide has the near-100%-incremental-margin royalty line guided DOWN about 15% sequentially to $69-75M while lower-margin (~60% GM) product chips rise to $110-116M: Rambus is deliberately swapping hundred-cent dollars for sixty-cent dollars. Licensing billings of $84.1M essentially matched reported royalty revenue and deferred revenue fell from $30.0M to $21.2M, so there is no hidden deferred cushion — $84M was the peak, not the run rate. Third, stock-based comp of $15.9M is 7.7% of revenue, making non-GAAP EPS 26% flatter than GAAP, diluted shares still rose 1.4%, and Rambus repurchased ZERO stock while it fell from $170 to $123 — with insiders selling 25 times in six months and buying nothing. Add an open criminal DOJ antitrust grand jury subpoena disclosed in the Q1 10-Q. Our owner-earnings DCF (free cash flow less stock comp, plus the $824.9M net cash back) lands near $72 a share; run backwards, today's $83.21 requires ~20% owner-earnings growth for five straight years, versus the 15% operating-income growth just delivered in the best quarter ever. Our call: AVOID, 3/5 — the crash took RMBS from absurd to merely expensive, and 'less overvalued' is not 'cheap.' We get interested below $72 and want it in the low $60s. Wall Street says Buy with a $147.40 average target (+77%), but most of those targets are dated April 28, 2026 — pre-crash — so we DIFFER, materially more cautious. Watch royalties and licensing billings every quarter. Not financial advice.

THE CALL: AVOID (3/5, A GREAT BUSINESS STILL PRICED FOR 20% GROWTH — WE WANT IT BELOW $72, IDEALLY IN THE LOW $60s) — base-case value ~$72.00 vs ~$83.21 today.

What to watch: royalty revenue stabilising above $80M a quarter instead of sliding, SG&A growth falling back below revenue growth, and management finally using the $824.9M of idle net cash to repurchase stock after a 51% drawdown would move us to a constructive call and likely an upgrade; the risks to respect are the opposite — further mix shift from ~100%-margin royalties into ~60%-margin product chips compressing operating margin, stock-based compensation staying above 7% of revenue while the share count rises, and an adverse outcome in the Department of Justice criminal antitrust investigation into the licensing model, which is the one tail risk that would genuinely impair the franchise rather than just the multiple

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Grifols, S.A. (GRFS) H1 2026 — Grifols, S.A. (NASDAQ: GRFS), the Barcelona-based plasma fractionator and one of only a handful of companies worldwide that can turn donated blood plasma into immunoglobulins, albumin and alpha-1 at scale, reported Half-Year 2026 results after the European close on July 28: revenue of €3,574M, +2.6% at constant currency but -2.8% as reported (a ~€197M FX translation drag), adjusted EBITDA of €854M at a 23.9% margin (+2.4% cc), and group profit of €227M, +28.7% YoY. Q2 standalone adjusted EBITDA of €472M at a 25.2% margin edged past ~€467M consensus. Free cash flow before M&A turned positive at +€91M versus -€12M a year earlier. But the headline profit jump is largely an accounting artifact: the April refinancing was treated under IFRS 9 as a debt modification rather than an extinguishment, producing a €109M NON-CASH gain in the finance result — more than the entire €50M increase in group profit. Strip it and H1 profit is nearer €145M, down ~18%. Net leverage was 4.2x on the credit-agreement basis — exactly where it stood a year ago — and 5.4x on full balance-sheet debt of €8,843M including leases. Adjusting for the €72M of LTM EBITDA consolidated from Haema and BPC Plasma (entities Grifols controls but whose equity its shareholders do not own) puts look-through leverage nearer 4.5x. Immunoglobulin grew +12.8% cc (subcutaneous/Xembify +17.7% H1, +33.9% in Q2), but albumin fell -14.2% cc (-20.8% in Q2) on a China price concession — and albumin is a joint product of the same litre of plasma. FY26 guidance was reaffirmed (adj. EBITDA margin ≥25%, +5-9% cc growth, FCF €500-575M), but H1 delivered 23.9% and +2.4%, so the second half must carry €409-484M of FCF, roughly 5x the H1 run rate. Critically, one GRFS ADR = one Class B NON-VOTING preference share (1:1), which trades at a persistent ~30% discount to the Madrid-listed Class A (GRF). Our EV-based frame — enterprise value of €17.26B against ~€1.83B of FY26E adjusted EBITDA, or 9.4x, bridged down through €8.84B of net debt and €2.43B of minority interests — lands a probability-weighted fair value near $7.75 per ADR versus ~$8.20 today. Our call: HOLD, 2/5. CSL trades at 10.7x EV/EBITDA with half the leverage, so the discount investors think they are buying has largely already closed. The ADR consensus (~$10.87, only 2 analysts) and the Madrid Class A consensus (€14.51, 12 analysts, ≈$11.48/ADR translated) are both well above us, so we DIFFER — materially more cautious.

Grifols (GRFS) just posted the kind of headline every turnaround investor wants to see — group profit up 28.7% to €227M — and almost nobody checked where it came from. In April, Grifols refinanced roughly €4.5B equivalent. Under IFRS 9 the accountants judged it a modification of existing debt rather than an extinguishment, which permits booking the change in present value straight to the income statement. Grifols booked a €109M gain. Entirely non-cash. Group profit rose from €177M to €227M — an increase of €50M. The accounting gain alone, after ~24.5% tax, is worth about €82M. Strip it out and H1 profit is nearer €145M, down roughly 18% year over year. Underneath that, the operating story is genuinely mixed-to-improving: H1 revenue €3,574M (+2.6% cc, -2.8% reported on a €197M FX drag), adjusted EBITDA €854M at a 23.9% margin, Q2 EBITDA €472M at 25.2% (a small beat), and free cash flow before M&A finally positive at +€91M versus -€12M. Immunoglobulin compounded +12.8% cc with subcutaneous Xembify up nearly 34% in Q2 — but albumin fell 20.8% in Q2 on a China price reset, and albumin comes out of the same litre of plasma as the immunoglobulin, so the revenue earned per litre collected has fallen. The refinancing pushed the maturity wall out to Q4 2028, a real achievement — but it cost 50-75bps more (SOFR+250 vs +200; Euribor+300 vs +225). Cash interest of €267M in the half annualizes to ~€534M, about 31 cents of every EBITDA euro, before a cent reaches an equity holder. And leverage? 4.2x on the company's credit-agreement basis — identical to a year ago. Strip the €72M of EBITDA consolidated from Haema and BPC Plasma, entities whose equity Grifols shareholders do not own, and look-through leverage is nearer 4.5x; on full balance-sheet debt of €8.8B it is 5.4x. One more thing every US buyer must know: the GRFS ADR is one Class B NON-VOTING share, trading ~30% below the Madrid voting Class A — and virtually every published price target is quoted on the Class A. Because a 4.5x-levered equity is a residual claim, we valued the enterprise and bridged down: EV €17.26B on ~€1.83B FY26E adjusted EBITDA is 9.4x, against CSL at 10.7x with half the leverage and ADMA at 9.4x with almost none. The discount people think they are buying has largely closed. Probability-weighted fair value: ~$7.75 per ADR versus ~$8.20 today. Our call: HOLD, 2/5 — a real operating turn attached to an equity that sits behind €8.8B of debt and €2.4B of minorities, with no margin of safety at this price. Wall Street is well above us and we DIFFER. Watch reported leverage, second-half free cash flow, and whether the US Biopharma IPO is real. Not financial advice.

THE CALL: HOLD (2/5, A REAL OPERATING TURN — BUT THE EQUITY IS A RESIDUAL CLAIM BEHIND €8.8B OF DEBT, AND THERE IS NO MARGIN OF SAFETY AT $8.20) — base-case value ~$7.75 vs ~$8.20 today.

What to watch: reported net leverage actually printing below 3.9x — reported, not guided — together with a second half that delivers the €409-484M of free cash flow the full-year guidance requires, and a concrete US Biopharma IPO filing with a date attached, would re-rate this equity hard, because a one-turn move in the EV/EBITDA multiple swings the ADR by roughly two dollars; the risks to respect are the mirror image — the US Biopharma IPO quietly disappearing after the July operating-split announcement, albumin pricing weakening further in China, second-half free cash flow missing, or the Class B non-voting discount staying stubbornly wide near 30%

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

The Coca-Cola Company (KO) Q2 2026 — The Coca-Cola Company (KO) reported Q2 2026 (three months ended July 3, 2026) before the open on July 28: net revenue $13.38B (+6.7% YoY, beating the ~$13.16B consensus), organic revenue +6% (4 pts concentrate sales, 2 pts price/mix), global unit case volume +5%, operating margin 34.9% vs 34.1% (comparable 35.6% vs 34.7%), reported EPS $1.03 (+16%) and comparable EPS $0.97 (+11%) vs a $0.93 estimate. Trademark Coca-Cola volume grew 5% — management's strongest quarterly growth in 17 years excluding the COVID rebound — helped by the FIFA World Cup hosted in North America, favorable European weather, and the easiest comparison of the year. FY26 guidance was raised: organic revenue ~5% (from 4-5%), comparable EPS growth 9-10% (from 8-9%) off a $3.00 FY25 base, and free cash flow ~$12.4B ($14.6B CFO less $2.2B capex). Coca-Cola Zero Sugar volume +16% in every geographic segment, fairlife +18% in H1, Powerade +8%, Diet Coke +7%; coffee -2%. The under-covered facts: CFO John Murphy stated the TWO-YEAR average volume growth is just 2%; price/mix of +2% is three points of pricing less a point of unfavorable mix; Asia Pacific grew volume 8% but price/mix fell 9% (Braun split it into rough thirds of investment timing, affordability initiatives and geo mix) with a value-share loss in India; EMEA comparable currency-neutral operating income fell 5%; reported EPS growth of 16% is only 9% on a comparable currency-neutral basis, and ~3 of the 9-10 points of FY guidance is currency. Net debt/EBITDA is 1.4x, below the 2-2.5x target, but the $2.12 dividend absorbs ~75% of guided FCF. The unresolved IRS transfer-pricing case (oral arguments heard at the Eleventh Circuit in late June 2026, decision 6-12 months out, ~$6B already deposited, exposure past $20B) is roughly 5% of market cap. The stock closed $84.07 on July 27, jumped 5.0% on the print to $88.27, and traded ~$90.24 intraday July 29 after an all-time high of $90.92 — about +30% in 12 months, essentially all multiple. Our owner-earnings DCF on $12.4B of FCF growing 6.5% for five years, fading to 3.25%, terminal 2.75%, at a 7.25% required return, lands fair value at $76. Our call: REDUCE, 3/5. Wall Street is Buy with a ~$96 average target (29 buy / 16 hold / 3 sell, 48 analysts; post-print UBS $104, TD Cowen $100, RBC $96), so we DIFFER — materially more cautious.

The most famous consumer brand on earth just posted its best volume quarter in seventeen years and broke out to an all-time high — and on the same call management quietly told you the two-year volume stack is 2%, not 5%. The Coca-Cola Company (KO) reported Q2 2026 (quarter ended July 3) before the open on July 28: net revenue $13.38B (+6.7%, a beat), organic revenue +6%, unit case volume +5%, operating margin 34.9% (comparable 35.6%), reported EPS $1.03 (+16%) and comparable EPS $0.97 (+11%) against a $0.93 estimate. Guidance was raised to ~5% organic revenue growth, 9-10% comparable EPS growth and ~$12.4B of free cash flow. The product news is genuinely good: Coca-Cola Zero Sugar volume grew 16% in every single geographic segment, fairlife grew 18% in the first half, Powerade 8%, Diet Coke 7%, relaunched Mr. Pibb over 20%, and Coca-Cola won the Marriott account back after 34 years. But the headline is flattered. CFO John Murphy said the quarter benefited from the easiest comparison of the year, a home FIFA World Cup activated across 180+ markets and 20 million retail outlets, and favorable European weather — and that on a two-year average, volume grew 2%. Price/mix of +2% is three points of pricing less a point of unfavorable mix; the double-digit pricing era is over. Asia Pacific bought 8% volume growth with a 9% decline in price/mix and lost value share in India; EMEA comparable currency-neutral operating income fell 5%; Q4 carries six fewer selling days. And of the 16% reported EPS growth, only 9% is comparable and currency-neutral — roughly 3 of the 9-10 points of full-year guidance is a weak dollar. Meanwhile the balance sheet is a fortress at 1.4x net leverage, but the $2.12 dividend already eats ~75% of guided free cash flow, and an unresolved IRS transfer-pricing case (oral arguments heard at the Eleventh Circuit in late June, decision 6-12 months away, ~$6B already deposited, total exposure past $20B) sits at ~5% of market cap with no reserve you can see. At ~$90.24 the stock trades at 27.5x forward comparable EPS and 31x guided free cash flow, versus PepsiCo at 18.9x — after a 30% twelve-month run that was almost entirely multiple expansion. Our owner-earnings DCF — $12.4B of free cash flow growing 6.5% a year for five years, fading to 3.25%, terminal 2.75%, discounted at a 7.25% required return — lands at $76. We're explicit about the tension: textbook CAPM on a 0.5-beta staple produces a 6.2% cost of capital at which KO looks roughly fair, but that means accepting a sub-4% real return on an equity forever, and we won't underwrite that. Run it backwards and today's price requires ~8.8% free-cash-flow growth for five years, or 4.2% forever, from a company whose two-year volume stack is 2%. Our call: REDUCE, 3/5 — an A-grade business at a price its own cash flows don't support; the mid-$70s is a fair price for the fortress and below $70 you're paid to wait. Wall Street is Buy with a ~$96 average target and post-print raises from UBS ($104), TD Cowen ($100) and RBC ($96), so we DIFFER and are materially more cautious. Watch the two-year volume stack and price/mix every quarter. Not financial advice.

THE CALL: REDUCE (3/5, AN A-GRADE BUSINESS AT A PRICE ITS OWN CASH FLOWS DON'T SUPPORT — THE QUARTER WAS FLATTERED BY AN EASY COMP, A HOME WORLD CUP AND A WEAK DOLLAR) — base-case value ~$76.00 vs ~$90.24 today.

What to watch: a two-year volume stack that holds above 3% without affordability giveaways, price/mix back above 3%, and a clean win at the Eleventh Circuit — which would also release the roughly $6 billion already deposited with the IRS — would let us move back to a HOLD or better, and in the mid-$70s we'd be buyers of the fortress; the risks that would make us more negative are the currency tailwind reversing (about 3 of the 9-10 points of guided EPS growth is FX), Asia Pacific price/mix staying deeply negative into next year as the company keeps buying volume with affordability packs, or an adverse ruling in the transfer-pricing case, where total exposure runs past $20 billion

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

The Boeing Company (BA) Q2 2026 — Boeing (BA) reported Q2 2026 (quarter ended June 30, 2026) before the open on July 28: revenue $24.56B (+8% YoY, beating the ~$24.25B consensus) on 171 deliveries (+14%), but a GAAP loss of $0.67/share and a core loss of $0.76 vs the ~$0.30 loss expected — more than double the miss, driven by a fresh $280M charge on the VC-25B (Air Force One) program that pushed cumulative losses on that $3.9B firm fixed-price contract past $3B. The number almost nobody led with: core operating earnings were $1 million on $24.56B of revenue — a 0.0% core operating margin. Free cash flow turned positive at $631M, but management attributed it to 'favorable working capital within the year': first-half advances and progress billings rose $4.66B (customer pre-payments, a liability) while inventory grew $3.86B, and six-month free cash flow is still NEGATIVE $823M. Segments: Commercial Airplanes $11.75B revenue at a -2.7% margin (lost $322M); Defense, Space & Security $7.48B at -0.2% (lost $15M); Global Services $5.34B at 18.1% (earned $968M) — so ~78% of revenue produces no operating profit and one segment carries the company. Real progress: the FAA capstone review cleared the 737 to 47/month (from a 38/month cap), a second 737 line activated in Everett in July, MAX 7 and MAX 10 certification flight testing is complete, and the 777X received TIA 4B — but first deliveries for all three are 2027 and Air Force One is 2028. Backlog hit a record $715B (6,200+ jets). Debt fell $8.4B to $45.9B, but that was funded by drawing down $5.7B of short-term investments plus $3.7B of cash — largely proceeds from selling Jeppesen/ForeFlight to Thoma Bravo for $10.55B — not by operations. Total equity is just $6.1B against $165.9B of assets. Our valuation frame is Path-to-Profitability + reverse DCF, because normalized FCF is not yet defensible. At the $221.56 July 28 close, 826.5M fully diluted shares (789.8M outstanding + 36.7M from the mandatory convertible preferred) and $25.9B net debt imply a ~$209B enterprise value — which even at a generous 8% discount rate and 3% terminal growth requires ~$13.3B of free cash flow every year forever. Boeing has produced that exactly once, in 2018, and on 586M shares. Our base case (FCF ramping to ~$8.5B by 2032) is worth ~$101; probability-weighted 25/45/30 gives ~$105. Our call: SELL, 2/5 — the turnaround is real, the price already pays for all of it. Wall Street is Buy with a ~$277 average target (36 buy / 13 hold / 5 sell, 54 analysts), so we DIFFER sharply.

Boeing (BA) just posted the most revealing number of its entire turnaround, and almost nobody mentioned it: core operating earnings of $1 million — on $24.56 billion of revenue. A 0.0% core operating margin. Q2 2026 (quarter ended June 30, reported before the open July 28) beat on revenue at $24.56B (+8%) on 171 deliveries (+14%), and missed badly on earnings: a core loss of $0.76 per share against the ~$0.30 loss expected, driven by another $280M charge on VC-25B — the Air Force One program, where cumulative losses on a $3.9 billion firm fixed-price contract have now passed $3 billion. Free cash flow turned positive at $631M, but Boeing's own language was 'favorable working capital within the year': across the first half, advances and progress billings (customer pre-payments — a liability) rose $4.66B while inventory grew $3.86B, and six-month free cash flow is still negative $823M. Segment by segment, Commercial Airplanes did $11.75B at a -2.7% margin and Defense did $7.48B at -0.2% — roughly 78% of revenue earning nothing — while Global Services alone earned $968M at an 18.1% margin. The genuine good news is real and deserves saying: the FAA capstone review cleared the 737 line to 47 a month (from a 38 cap), a second 737 line came up in Everett, MAX 7 and MAX 10 certification flight testing is complete, the 777X got TIA 4B, and backlog hit a record $715 billion across 6,200+ airplanes. But read the dates — first deliveries are all 2027, Air Force One is 2028. And the $8.4B of debt repaid in the half wasn't earned; it was funded by drawing down $5.7B of investments and $3.7B of cash, largely the proceeds of selling Jeppesen and ForeFlight to Thoma Bravo for $10.55B — which is also why Global Services' margin slipped from 19.9% to 18.1%. Total equity is $6.1B against $165.9B of assets and $88B of inventory. Because normalized free cash flow isn't defensible yet, we value BA with a Path-to-Profitability plus reverse DCF. At the $221.56 July 28 close, 826.5 million fully diluted shares (including 36.7M from the mandatory convertible preferred) and $25.9B of net debt put the enterprise near $209 billion — which even at a generous 8% discount rate and 3% terminal growth demands roughly $13.3 billion of free cash flow every year, forever, starting now. Boeing has hit that once, in 2018, on 586 million shares. Our own base case is constructive — FCF ramping to about $8.5B by 2032 — and it's worth about $101 a share; probability-weighted, ~$105. Our call: SELL, 2/5. This is not a bet against the turnaround, which is real and improving under Kelly Ortberg. It's a bet against the price. Wall Street is a Buy with a ~$277 average target across 54 analysts, so we differ sharply — and we say plainly how we could be wrong: the market has paid up for Boeing's duopoly optionality for years. Watch the Commercial Airplanes operating margin above all. Not financial advice.

THE CALL: SELL (2/5, THE TURNAROUND IS REAL — THE PRICE ALREADY PAYS FOR ALL OF IT, AND MORE) — base-case value ~$105.00 vs ~$221.56 today.

What to watch: the one number that would flip us bullish is the Commercial Airplanes operating margin — get it durably above 5% at a 47-a-month 737 rate, with two consecutive quarters of positive free cash flow that is NOT driven by customer advances, and the base case moves up fast enough to justify a much higher price; the risks that would push us lower are the mirror image — another fixed-price charge like the $280M VC-25B hit, a certification slip on the MAX 7, MAX 10 or 777X that pushes first deliveries past 2027, or any inventory write-down landing against just $6.1B of shareholders' equity beneath $88B of inventory

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Teradyne, Inc. (TER) Q2 2026 — Teradyne, Inc. (TER), one of the two companies that dominate automated semiconductor test equipment alongside Advantest of Japan, reported Q2 2026 (quarter ended June 28, 2026) after the close on July 28. Revenue was $1.329B, +103.9% YoY from $651.8M and up 3.6% sequentially, exceeding the high end of the company's own guidance and marking a second consecutive quarter of record revenue. GAAP gross margin was 59.8% versus 57.2% a year ago; GAAP income from operations was $437.8M (32.9% margin) versus $90.7M (13.9%); GAAP net income attributable to Teradyne $374.5M, or $2.38 per diluted share versus $0.49; non-GAAP net income $389.0M, or $2.47 per diluted share versus $0.57. Revenue split: Semiconductor Test $1,122M (84% of total), Product Test $107M, Robotics $100M. Management's headline attributed the quarter to record Memory revenue driven by continued strength in DRAM and a resurgence in NAND final test; CEO Greg Smith said all three business groups saw year-on-year market expansion and that a rapid increase in wafer fab equipment investment sets the stage for continued growth in 2027 and beyond. First half 2026: revenue $2.611B versus $1.337B, GAAP diluted EPS $4.91 versus $1.10. Q3 2026 guidance is revenue of $1,200M to $1,300M with GAAP diluted EPS of $1.79 to $2.09 and non-GAAP diluted EPS of $1.85 to $2.15. Balance sheet: cash $349.5M plus marketable securities of $167.6M against zero debt (the $200M of short-term borrowings outstanding at December 31 was repaid, and a $300M revolver draw within the quarter was repaid within the quarter); equity method investment carried at $515.0M. Q2 operating cash flow $469.1M versus $182.1M, capital expenditures $90.7M versus $50.4M, implying free cash flow of about $378M; first-half operating cash flow $734.3M and capex $155.4M for roughly $579M of free cash flow. The quarterly dividend was $0.13 per share. The under-covered numbers: first, non-GAAP operating margin FELL from 37.5% to 33.7% sequentially and non-GAAP operating income declined in absolute dollars from $480.4M to $448.3M on $46.5M MORE revenue, because operating expenses rose $48.9M (S&A +15%, E&D +15%) — a negative sequential incremental margin at record revenue, partly reflecting the MultiLane Test Products joint venture that closed in the quarter and added $142.8M of goodwill and a $36.2M noncontrolling interest. Second, sequential revenue growth has decelerated from +41% to +18% to +3.6%, and the Q3 guide midpoint of $1,250M is DOWN about 6% sequentially with non-GAAP EPS falling 19% from $2.47 to about $2.00. Third, Teradyne repurchased only $74.2M of stock in the first half of 2026 versus $274.9M in the first half of 2025 — a 73% cut while the shares tripled. The stock closed at $90.15 a year ago, reached a $483.84 closing high on June 30, 2026, opened at about $367.90 on July 29 (up nearly 15% on the print) and traded back near $333 by mid-morning, erasing the entire gap.

Teradyne just reported the best growth quarter in its modern history and the market refused to pay for it. Q2 2026 (quarter ended June 28): revenue $1.329 billion, up 103.9% year over year and above the high end of the company's own guidance; GAAP gross margin 59.8% versus 57.2%; operating income $437.8 million versus $90.7 million, a 32.9% operating margin against 13.9%; non-GAAP EPS $2.47 versus $0.57 and GAAP EPS $2.38 versus $0.49. Semiconductor Test was $1,122 million of the total, about 84% of the company, driven by record memory revenue on DRAM strength and, in management's own words, a resurgence in NAND final test. September guidance of $1.20 to $1.30 billion of revenue and $1.85 to $2.15 of non-GAAP EPS landed far above a Street sitting near $1.06 billion and $1.55. The stock opened up almost 15% at roughly $368 — and gave the entire gap back within the hour, trading near $333. So why are we not buying? Because of three numbers almost nobody wrote about. First, compare this quarter to LAST quarter instead of last year: non-GAAP operating margin fell from 37.5% to 33.7%, and non-GAAP operating income went DOWN in absolute dollars, from $480.4 million to $448.3 million, on $46 million MORE revenue. The incremental margin on the last dollar of growth was negative. Second, the sequential line: quarter-over-quarter revenue growth ran +41%, then +18%, then +3.6%, and the guide midpoint is minus 6%. Teradyne is not being punished for a bad quarter; it is being repriced for a decelerating one. Third, and loudest: management repurchased just $74 million of stock in the first half of 2026 against $275 million in the first half of 2025 — buybacks cut 73% while the shares tripled. Their own capital allocation is telling you what they think this is worth. The franchise is genuinely excellent — a two-player oligopoly, mission-critical product, near-60% gross margins, zero debt, and AI accelerators and high-bandwidth memory that require more test time per wafer, not less. We grade it an A-minus and we think management has handled the windfall correctly. But memory test is the most violent cycle in semiconductors, and when a NAND final-test resurgence is carrying your record quarter, history says you are nearer the top than the bottom. We run two honest futures on owner earnings — net income plus D&A minus capex, roughly $1.2 billion in 2026. A cyclical path where memory rolls over in 2028 is worth about $156 a share at a 9% discount. A full AI-test secular path, owner earnings nearly tripling to $3.35 billion and holding, is worth about $327. Weighted 55% to the secular case, fair value lands near $250 against roughly $333 today — about 25% below. Note what that means: even our bull case sits BELOW today's price. The market is not paying for a good outcome; it is paying for something better than our best one. Our call: HOLD, 2 out of 5. Wall Street is at Buy — roughly 20 buys, 11 holds, no sells across about 31 analysts — with an average target near $420 and recent raises from UBS to $500, Bank of America to $525, and Susquehanna and Cantor Fitzgerald both to $550. So we differ, and we are more cautious. This is a judgment about price, not about the company. Not financial advice.

THE CALL: HOLD (2/5, A REAL BOOM, PRICED AS IF IT NEVER CYCLES — A JUDGMENT ABOUT THE PRICE, NOT THE COMPANY) — base-case value ~$250.00 vs ~$333.00 today.

What to watch: what would move us more bullish is the sequential line turning back up — a December-quarter guide above the September quarter with gross margin holding at or above 60%, which would mean this deceleration was a pause rather than a peak and would lift our fair value materially; evidence that AI-accelerator and high-bandwidth-memory test intensity is structurally raising test time per wafer rather than pulling demand forward; and management restarting buybacks in size, since their 73% cut in the first half is currently the loudest signal in the release; the risks that would deepen our caution are the mirror image — a second consecutive sequential decline in the guide, gross margin sliding out of the high fifties, non-GAAP operating margin continuing to fall while revenue sets records, any sign that the resurgence in NAND final test was one-off restocking rather than durable demand, and continued negative incremental margins as operating expenses outgrow revenue

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Seagate Technology Holdings plc (STX) Q4 FY2026 — Seagate Technology Holdings plc (STX), one of only two companies that matter in nearline hard disk drives, reported fiscal Q4 2026 (quarter ended July 3, 2026) after the close on July 28. Revenue was $3.629B, +48.5% YoY; GAAP gross margin 52.3% and non-GAAP gross margin 52.7%, against 37.4% and 37.9% a year ago; GAAP diluted EPS $5.58 (vs $2.24) and non-GAAP diluted EPS $5.71 (vs $2.59); income from operations $1.559B versus $568M, a 43% operating margin. Cash flow from operations was $1.3B and free cash flow $1.118B; the company retired $302M of debt and returned $283M to shareholders. Full fiscal year 2026: revenue $12.195B (+34%), GAAP diluted EPS $13.90, non-GAAP diluted EPS $15.58, cash flow from operations $3.674B, record free cash flow $3.105B on capital spending of just $569M, $1.4B of debt retired and $810M returned. Shareholders' equity swung from a $453M deficit to positive $2.167B; net debt is about $1.9B. The board declared a $0.74 quarterly dividend payable October 7, 2026. Guidance for fiscal Q1 2027 is revenue of $4.1B +/- $100M (about +56% YoY) and non-GAAP diluted EPS of $7.30 +/- $0.20, against $2.61 in the year-ago quarter. On the call management said hard drive exabyte shipments reached 218 EB (+34% YoY) with roughly 90% going into data centers; data center revenue was $2.9B, +57% YoY on 195 exabytes, or 81% of total sales; HAMR-based Mozaic products exited fiscal 2026 at about 40% of the nearline exabyte run rate; and the vast majority of nearline exabytes are already allocated under long-term supply agreements through calendar 2028, with customers seeking to extend into 2029 and beyond. The under-covered number: revenue grew 48.5% while exabytes grew 34%, so revenue per exabyte rose roughly 11% — a third of the growth is price and mix, not volume, which is what a supply shortage looks like rather than a productivity gain. The stock closed a year ago at $147, closed as high as $1,094 on June 22, 2026, and traded near $784 after this print — about 28% below that closing high even as earnings accelerated.

Seagate just printed the best quarter in its 47-year history, and the stock is still 28% below its June high. Fiscal Q4 2026 (ended July 3): revenue $3.629B, up 48.5% year over year; GAAP gross margin 52.3% and non-GAAP 52.7%, against 37.4% and 37.9% a year ago — nearly fifteen points of gross margin expansion in twelve months, on hard drives; GAAP diluted EPS $5.58 versus $2.24; non-GAAP diluted EPS $5.71; income from operations $1.559B versus $568M, a 43% operating margin. For the full year: revenue $12.195B (+34%), non-GAAP EPS $15.58, operating cash flow $3.674B and a record $3.105B of free cash flow on only $569M of capital spending. Management retired $1.4B of debt and turned a $453M equity deficit into $2.167B of positive equity. September-quarter guidance is $4.1B of revenue (+56% YoY) and $7.30 of non-GAAP EPS against $2.61 a year ago, and the vast majority of nearline exabytes are already committed under long-term supply agreements through calendar 2028. The industry structure is genuinely better than it was: HDD consolidated from more than a dozen makers to Seagate, Western Digital and a much smaller Toshiba, and Seagate's HAMR-based Mozaic platform exited the year at roughly 40% of the nearline exabyte run rate. So why are we not buying? Because of one number almost nobody wrote about: revenue grew 48.5% while exabytes grew only 34%, meaning revenue per exabyte rose about 11%. That is not a productivity miracle — it is scarcity rent, and rents attract supply. A 52% gross margin has never happened in this industry, and roughly two-thirds of what this stock is worth depends on what Seagate earns in 2031, which nobody knows. We run two honest futures. A cyclical path that peaks in fiscal 2028 near $7.2B of free cash flow and normalizes to $4.6B is worth about $294 a share at a 9% discount. A full AI-storage secular path, free cash flow compounding roughly 18% a year to $12.8B and holding, is worth about $832. Weighted 50/50 — and 9% is a friendly discount rate for a stock with a 2.07 beta, where CAPM argues closer to 14% — fair value lands near $560 against roughly $784 today. Today's price sits almost exactly on our bull case, which means you are paying for the best outcome and absorbing the risk of every other one. Our call: HOLD, 2 out of 5. Wall Street is at Buy/Strong Buy with average targets running $890 to $1,070 and recent raises from Cantor Fitzgerald and Citigroup at $1,300 — so we differ, and we are more cautious. This is a judgment about price, not about the company. Not financial advice.

THE CALL: HOLD (2/5, A REAL BOOM, PRICED AS IF IT NEVER ENDS — A JUDGMENT ABOUT THE PRICE, NOT THE COMPANY) — base-case value ~$560.00 vs ~$784.00 today.

What to watch: what would move us more bullish is durable evidence that the contracted window keeps extending — long-term nearline supply agreements stretching into 2029 and 2030 at similar pricing, which is what strengthens the terminal-value case that today's price already assumes, alongside gross margin holding above 50% as competitor capacity comes online; the risks that would deepen our caution are the mirror image — gross margin falling while exabytes still rise (the signal that supply has caught demand), Western Digital or Toshiba announcing meaningful nearline capacity additions, any hyperscaler guiding to slower storage purchases, or the long-term agreements failing to extend past calendar 2028, since roughly two-thirds of the value in this stock sits in fiscal 2031 and beyond

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

KLA Corporation (KLAC) Q4 FY2026 — KLA Corporation (KLAC), the dominant supplier of semiconductor process-control (inspection and metrology) equipment with roughly 58% market share, reported fiscal Q4 2026 (quarter ended June 30, 2026) after the close on July 28. Revenue was a record $3.658B, +15.2% YoY and above the midpoint of guidance; non-GAAP EPS of $1.05 beat the ~$1.02 consensus; non-GAAP gross margin of 62.4% landed at the upper end of guidance. GAAP net income was $1.363B and GAAP diluted EPS $1.04 — the low per-share figure reflects the 10-for-1 stock split effected June 11, 2026 (1.315B diluted shares). FY26: revenue $13.579B (+11.7%), GAAP net income $4.831B (+18.9%), non-GAAP EPS $3.76. Guidance for Q1 FY27 was $4.0B +/- $200M (about +25% YoY, above the ~$3.92B consensus) with non-GAAP EPS of $1.16, and management raised its calendar-2026 wafer-equipment market view to the low $150B range from $140B+. Yet the stock fell ~9% after the print, on top of a 6.2% decline that session — about 42% below its June 30 closing high of $301.71. Two under-covered facts explain the reaction. First, wafer inspection — KLA's highest-margin, highest-share franchise — grew just 1% YoY and fell from ~56% to 49% of revenue; growth came from lower-margin patterning (+61%), PCB and component inspection systems (+96%) and services (+17%), which is why non-GAAP gross margin actually declined from 63.2% to 62.4% on 15% more revenue, and why September gross margin is guided flat at 62.5% on ~10% more revenue. Second, cash conversion deteriorated: FY26 free cash flow was $3.767B versus $3.747B — flat — while net income rose 19%, so FCF/net income fell to 78% from 92% in FY25 and 110% in FY24; Q4 FCF fell 23% YoY to $817M as receivables consumed $586M in the quarter and ended the year +28% against 15% revenue growth. KLA still returned $3.348B (89% of FCF) via buybacks and its 17th straight dividend increase. China was 26% of revenue. Our owner-earnings DCF on a ~$4.7B base, weighted 70% to the AI-secular path at a 9% discount rate, lands fair value near $110 versus ~$174 — about 37% below the price. Our call: HOLD, 2/5 — an A+ franchise whose 2030 plan is already in the price. Wall Street is at Buy (28 buy / 14 hold / 2 sell) with a ~$229 average target implying +32%, so we DIFFER and are materially more cautious.

KLA Corporation (KLAC) just did something unusual: it printed the best quarter in its history, beat on earnings, guided above consensus, raised its forecast for the entire wafer-equipment market — and the stock fell anyway, leaving it about 42% below its June high. KLA is the near-monopoly of semiconductor process control, the inspection and metrology step that catches defects while chips are being built; it holds roughly 58% of that market and earns like it, with 62%+ gross margins, 42%+ operating margins and a return on equity near 76%. Fiscal Q4 2026 (ended June 30): revenue a record $3.658B (+15.2% YoY), non-GAAP EPS $1.05 versus ~$1.02 expected, non-GAAP gross margin 62.4% at the top of guidance, GAAP net income $1.363B. Full year: revenue $13.579B, GAAP net income $4.831B (+18.9%), non-GAAP EPS $3.76. September guidance is $4.0B +/- $200M, roughly +25% YoY and above the Street, with the calendar-2026 wafer-equipment market raised to the low $150B range from $140B+, backlog around $12.5B, and advanced-packaging process-control revenue guided to about $1.1B in 2026, up more than 70%. So why did it sell off? Two things the coverage largely skipped. First, the mix: wafer inspection — the crown-jewel franchise where KLA's share and pricing power are greatest — grew only 1% year over year and slipped from about 56% to 49% of revenue. The 15% growth came from structurally lower-margin lines: patterning +61%, PCB and component inspection systems +96%, services +17%. That is precisely why non-GAAP gross margin went down, from 63.2% to 62.4%, on 15% more revenue — and why September margin is guided flat at 62.5% despite roughly 10% more revenue, with management also flagging that memory input costs (KLA buys memory chips for its own tools) likely bite through 2027 and that repricing existing orders is limited. Second, the cash: FY26 free cash flow was $3.767B against $3.747B a year earlier — essentially flat — while net income rose 19%. Free cash flow as a share of net income fell to 78%, from 92% in FY25 and 110% in FY24, the weakest in at least eight years. In the June quarter alone FCF fell 23% to $817M as receivables absorbed $586M and finished the year up 28% versus 15% revenue growth. KLA still returned $3.348B, about 89% of free cash flow, and has targeted more than 90% going forward. China remains 26% of revenue, second only to Taiwan at 31%, in a business governed by export controls. Our owner-earnings DCF uses a ~$4.7B base (net income plus D&A, less capex, with a haircut for the working capital this business now consumes; reported FCF was $3.767B) and runs a cyclical path compounding at 8% and an AI-secular path at 16%. At a 9% discount rate those are worth about $75 and $123 per share; weighted 70% to the bull case, fair value is roughly $110 against a price near $174 — our value sits about 37% below the market. Even management's own 2030 target of $8.40 in split-adjusted non-GAAP EPS, at a generous 25x and discounted back four years at 9%, is only about $149. Our call: HOLD, 2/5 — this is a downgrade of the price, not the company; we'd get interested below roughly $120 and want real margin of safety under about $105. Wall Street disagrees: 28 buy, 14 hold, 2 sell, average target near $229, about 32% above the price, so we DIFFER and are more cautious. Watch free cash flow and gross margin every quarter. Not financial advice.

THE CALL: HOLD (2/5, A WORLD-CLASS FRANCHISE WITH 2030 ALREADY IN THE PRICE — A DOWNGRADE OF THE PRICE, NOT THE COMPANY) — base-case value ~$110.00 vs ~$174.00 today.

What to watch: hard evidence that calendar 2027 is another up year rather than a digestion year — backlog pushing durably past $12.5B and wafer inspection re-accelerating from its 1% growth — combined with gross margin actually breaking upward toward the 63.5%+ the 2030 target model requires, instead of drifting down while revenue climbs, would restore the compounding case and move us up; the risks that would deepen our caution are the mirror image — any pause in wafer-equipment spending, a new export-control round hitting the 26% China exposure, memory input costs persisting past 2027, or receivables and inventory continuing to grow roughly twice as fast as revenue and holding free-cash-flow conversion below 80%

Also on YouTube: @ChargedAlpha

DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.